What does American Healthcare do and what are its main business segments?

What is the revenue and EPS growth rate for American Healthcare year over year?

What is American Healthcare's latest dividend and current dividend yield?

What were the key takeaways from American Healthcare’s earnings call?

What guidance did American Healthcare's management provide for the next earnings period?

What were the key takeaways from American Healthcare's earnings call?

What is the market's earnings forecast for American Healthcare next quarter?

What factors drove the changes in American Healthcare's revenue and profit?

- **2025 Performance:** Total NOI +14.2%, NFFO +22% to $1.72/share.
- **2026 Outlook:** NFFO $1.99-$2.05, same-store NOI 7%-11% (SHOP 15%-19%).
- **Acquisition Strength:** $950M 2025 buys, $230M pipeline at 5.2%-6.0% cap rates.
- **Operational Excellence:** SHOP 25.2% NOI growth, Trilogy 18.4% with 90.6% occupancy.
- **Strategic Leverage:** Revenue management system, 3.4x debt/EBITDA liquidity.

**【CEO & Management Opening Remarks】**
- Jeff Hanson emphasized continuity of strategy and confidence in the team during his interim CEO tenure, with Danny Prosky recovering well at home.
- 2025 results reflect strong operational execution, with total portfolio same-store NOI growth of 14.2% (Q4: 11.8%).
- 2026 guidance: NFFO $1.99-$2.05/share, same-store NOI growth 7%-11% (SHOP: 15%-19%, Trilogy: 8%-12%).

**【COO Operational Update】**
- SHOP NOI +25.2% YoY, occupancy 90.6% (up 290bps), driven by rate/mix/expense control.
- Trilogy NOI +18.4%, occupancy 90.6% (up 275bps), Medicare/MedAdvantage penetration +220bps.
- Revenue management system in Trilogy being piloted with SHOP operators for dynamic pricing.

**【CFO Financial Review】**
- 2025 NFFO $1.72/share (+22%), funded by $950M acquisitions (SHOP 76.9% of NOI).
- 2026 pipeline: $230M awarded deals, $117.5M closed YTD, 3.4x debt/EBITDA.
- Forward equity agreements provide $287M liquidity for 2026 spend.

**【Q&A Highlights】**
- **Acquisition Environment:** Focus on newer, higher acuity assets with 5.2%-6.0% cap rates, 70% off-market deals.
- **SHOP Growth:** 17% midpoint guidance reflects 90%+ occupancy, rate/mix leverage.
- **Trilogy Mix Shift:** Medicare Advantage contracts leveraging 5-star quality ratings.
- **Development Pipeline:** $150M-$200M annual Trilogy expansions with aligned operator incentives.
- **Triple-Net Stability:** Methodist Hospital (AA- rated) investing $25M in Southlake facility.

American Healthcare REIT, Inc.(AHR)-20260227-2025 Q4 Earnings call transcript

- **Record Growth**: 16.4% same-store NOI growth, 21.7% at Trilogy, 25.3% at SHOP, and 90%+ occupancy across segments.
- **Strategic Acquisitions**: $575M year-to-date, $450M pipeline, and $177M development pipeline for 20%+ FFO growth.
- **Financial Strength**: 3.5x debt-to-EBITDA, $275M forward equity sales, and narrowed 2025 FFO guidance to $1.69-$1.72.
- **Medicare Advantage**: 7.2% resident days (vs. 5.8% 2024), driving 270 bps NOI margin expansion.
- **Focus Shift**: Exiting MOBs (<17% of NOI) to prioritize high-acuity RIDEA assets.

**Management Opening Remarks**
- Alan Peterson welcomed participants, highlighting Q3 2025 results, including 16.4% same-store NOI growth and 7.2% Medicare Advantage resident days. The company increased 2025 normalized FFO guidance to $1.69-$1.72 per share.

**CEO Commentary**
- Danny Prosky reported 7 consecutive quarters of double-digit same-store NOI growth, driven by Trilogy (21.7%) and SHOP (25.3%). Year-to-date acquisitions reached $575M, with a $450M pipeline. Emphasized disciplined capital deployment and strategic operator partnerships.

**COO Commentary**
- Gabriel Willhite detailed Trilogy's 90.2% occupancy and 7% ADR growth, alongside SHOP's 90%+ spot occupancy. Highlighted Medicare Advantage's 270 bps NOI contribution and the pilot of Trilogy's revenue management system across other operators.

**CIO Commentary**
- Stefan K. Oh announced $575M in 2025 acquisitions, including new partnerships with WellQuest and Great Lakes. The $177M development pipeline targets high-yield projects. Focused on accretive, relationship-driven growth.

**CFO Financial Commentary**
- Brian Peay reported Q3 normalized FFO of $0.44 (22% YoY growth) and narrowed 2025 guidance to $1.69-$1.72. Debt-to-EBITDA improved to 3.5x, with $275M in forward equity sales for capital flexibility.

**Q&A Highlights**
- **Occupancy & Pricing**: 90%+ occupancy across segments; expect 200+ bps ADR growth vs. inflation. Medicare Advantage penetration rising (7.2% Q3 2025 vs. 5.8% 2024).
- **Competitive Environment**: Pipeline growth driven by new operator partnerships; disciplined underwriting maintains accretion.
- **Capital Deployment**: $575M in 2025 acquisitions, $450M pipeline, and $177M development pipeline support 20%+ FFO growth.
- **MOB Strategy**: Divesting lower-margin MOBs (now <17% of NOI) to focus on high-growth RIDEA segments.

American Healthcare REIT, Inc. (AHR) Q3 2025 Earnings Call Transcript

- **Record NOI Growth**: 13.9% total portfolio same-store NOI growth, driven by 18.3% in Trilogy and 23% in SHOP.
- **Acquisition Momentum**: $255M in Q2 closes, $300+M pipeline focused on RIDEA and high-quality assets.
- **Financial Strength**: NFFO up 27% YoY to $0.42, net debt/EBITDA at 3.7x, with updated 2025 guidance of $1.64-$1.68.
- **Medicare Advantage Expansion**: 7.2% of resident days (vs. 5.8%), with rates 79% higher than Medicaid.
- **Outpatient Recovery**: 1% YoY NOI growth, nearing stabilization with 10+ assets in disposition pipeline.

**【Management Opening Remarks】**
- Alan Peterson introduced the executives and outlined the call structure, emphasizing forward-looking statements and non-GAAP financial measures.

**【CEO Commentary】**
- Reported strong Q2 performance with 13.9% total portfolio same-store NOI growth.
- Highlighted $255 million in acquisitions and a $300+ million pipeline, focusing on RIDEA structures.
- Noted net debt to EBITDA improved to 3.7x from 4.5x, driven by organic growth and equity raises.
- Emphasized secular growth in seniors housing due to supply-demand mismatch and aging demographics.

**【COO Operational Update】**
- **Trilogy Segment**: 18.3% NOI growth, 88.9% occupancy, 7.8% rate growth, and 7.2% Medicare Advantage resident days (vs. 5.8% prior year).
- **SHOP Segment**: 23% NOI growth, 87.5% occupancy, and 6.6% RevPOR growth.
- Operational improvements include revenue management programs, wage monitoring, and internal referrals boosting margins.

**【CIO Investment Activity】**
- Closed $255 million in acquisitions, including $118 million Trilogy joint venture buyout and $33.5 million SHOP deals.
- Pipeline remains robust at $300+ million, with focus on high-quality, newer assets in assisted living and memory care.
- Year-1 yields on stabilized assets range from low-6% to high-7%, with upside from operating leverage.

**【CFO Financial Results】**
- Q2 normalized FFO of $0.42 (27% YoY increase), driven by organic growth and capital markets activity.
- Raised $204.3 million via ATM at $34.72 average price and settled $127.8 million forward ATM at $35.96.
- Updated 2025 guidance: NFFO $1.64-$1.68 (prev. $1.58-$1.64), total portfolio NOI 11%-14% (prev. 9%-13%).

**【Q&A Highlights】**
- **Occupancy & Pricing**: Expect peak occupancy in mid-90s, with disciplined rate growth (e.g., Medicare Advantage rates 79% higher than Medicaid).
- **Pipeline Assets**: New operator relationships (e.g., Great Lakes Management) focus on high-quality, newer buildings with below-replacement cost pricing.
- **Outpatient Medical**: Improved asset management led to 1% YoY NOI growth; expect continued stabilization with 10+ assets in disposition pipeline.
- **Capital Strategy**: Balanced use of equity (ATM, forward ATM) and debt to fund growth, maintaining net debt/EBITDA below 4x.


American Healthcare REIT (AHR)-8 Aug 25-2025 Q2 Earnings call transcript

- **Record Q1 Growth**: 15.1% same-store NOI driven by Trilogy (19.8%) and SHOP (30.7%) segments. 
- **Guidance Hike**: Full year same-store NOI raised to 9-13% (prev 7-10%), with SHOP segment now 20-24%. 
- **$300M+ Pipeline**: Over $300M in accretive deals, 80%+ in SHOP, with 65%+ expected to close in H2. 
- **Margin Expansion**: 5% YoY opex decline, 6% RevPOR growth in SHOP, and 4.5x net debt/EBITDA. 
- **Medicaid/Medicare Tailwinds**: July rate resets + Medicare Advantage partnerships driving skilled nursing growth.

**【CEO Summary Section】**
- Q1 2025 same-store NOI growth of 15.1%, driven by Trilogy (19.8%) and SHOP (30.7%) segments. 
- Full year guidance raised: Total portfolio same-store NOI growth to 9-13% (prev 7-10%), Trilogy to 12-16% (prev 10-12%), SHOP to 20-24% (prev 18-22%).
- $300M+ acquisition pipeline with 65%+ expected close in H2 2025.
- Net debt/EBITDA at 4.5x, with ATM program raising $48M in Q1.

**【COO Operational Highlights】**
- Trilogy's integrated care model delivered 19.8% NOI growth, driven by skilled nursing demand and CMS 5-star ratings (avg 4.8/5). 
- SHOP segment saw 30.7% NOI growth, 8.8% RevPOR increase, and 2% margin expansion despite flu season headwinds.
- Q1 move-ins up sharply post-Q1, with spring/summer demand expected to accelerate.

**【CIO Investment Update】**
- Q1 closed $65M SHOP acquisition and $16.1M Trilogy lease buyout. 
- Pipeline of >$300M in accretive deals, 80%+ in SHOP, with avg per-unit cost $200k and mid-6%+ going yields.
- Disposed $40M in lower-growth assets, with remaining 14 assets under active marketing.

**【CFO Financial Results】**
- Q1 NFFO of $0.38/share (+26% YoY), raising full year guidance to $1.58-1.64 (prev $1.56-1.60). 
- Operating expenses down 5% YoY, with disciplined capital allocation via ATM and asset recycling.
- 71% of NOI from operating portfolio, up from 68% last quarter.

**【Q&A Key Takeaways】**
- Pipeline deals expected to close late Q3-early Q4, with >90% under LOI or contract. 
- MOB and triple-net portfolios shrinking (110→80+ MOBs, <10% NOI), with focus on SHOP/Trilogy growth. 
- Trilogy Medicaid rates reset July 1, with inflation + quality-based upside. 
- Medicare Advantage partnerships expanding, driving skilled nursing occupancy growth. 
- Dynamic pricing and reduced concessions key to margin expansion in SHOP segment.

American Healthcare REIT (AHR)-9 May 25-2025 Q1 Earnings call transcript

- **Exceptional Growth**: 2024 same-store NOI up 17.7%, with Trilogy (71% of NOI) and SHOP (65% Q4 growth) leading. 2025 guidance: 7-10% total portfolio growth.
- **Strategic Investments**: $650M+ in 2024 external growth, including 2 new SHOP acquisitions and $140M in Trilogy developments. Debt/EBITDA reduced to 4.3x.
- **Resilient Model**: Medicaid risk minimal (21% Trilogy exposure), with ability to pivot to private pay. 2025 development pipeline supports low double-digit returns.
- **Financial Health**: 2024 NFFO of $1.41, 2025 guidance of $1.56-$1.60. ATM program reduces leverage, positioning for accretive opportunities.


**【CEO Overview】**
- American Healthcare REIT achieved 21.6% Q4 and 17.7% full-year 2024 same-store NOI growth, driven by the Trilogy and SHOP segments. Trilogy contributed 71% of total NOI, with 28% Q4 and 23.8% full-year growth. SHOP segment grew 65% Q4 and 52.8% annually.
- 2025 guidance includes $650M+ in external growth, with 2 new SHOP acquisitions and $140M in Trilogy developments. Net debt/EBITDA improved to 4.3x from 8.5x in 2023.
- Medicaid policy risks are manageable, with Trilogy's 21% Medicaid exposure focused on short-term care and easily convertible to private pay.

**【COO Operational Highlights】**
- Trilogy margins reached pre-pandemic levels (near 19%), with 40% of new admits converting to AL/IL. SHOP margins expanded 700bps Q4 and 500bps annually, with RevPAR growth outpacing expenses.
- 2025 outlook: 10-12% Trilogy NOI growth, 18-22% SHOP growth, and 7-10% total portfolio growth. Q1 2025 NOI may face headwinds from seasonal factors and expense resets.

**【CFO Financial Details】**
- 2024 NFFO per share: $1.41 (within guidance). 2025 guidance: $1.56-$1.60, excluding unannounced transactions. ATM program raised $121M to reduce leverage.
- Capital allocation: $650M+ in 2024 external growth, with 2025 focus on accretive acquisitions and development. Dispositions of lower-growth assets (e.g., $140M Q4) support portfolio quality.

**【Q&A Key Takeaways】**
- **Policy Risk**: Medicaid cuts unlikely to materially impact Trilogy, given 21% exposure and ability to pivot to private pay. Industry-wide skilled nursing closures could create market share opportunities.
- **Development Pipeline**: 2025 plans include $140M in Trilogy developments (new campuses, villas, expansions). New assets typically stabilize in 12-18 months, with low double-digit yields.
- **SHOP Growth**: 2025 RevPAR growth expected to outpace expenses, driven by occupancy gains and pricing strategies. Industry supply constraints support long-term fundamentals.


Actual	-0.42	-0.04	0.01	-0.03	-0.21	-0.04	0.06	0.33	0.06
Forecast	-0.3133	-0.3533	0	-0.0067	0.0833	0.05	0.12	0.1567	0.1549
Surprise	-34.06%	+88.68%	0.00%	-347.76%	-352.10%	-180.00%	-50.00%	+110.59%	-61.27%

Actual	482.58M	499.53M	504.58M	523.81M	542.74M	540.60M	542.50M	571.10M	604.08M
Forecast	471.37M	491.79M	506.55M	474.26M	541.04M	537.37M	541.93M	552.52M	609.48M
Surprise	+2.38%	+1.58%	-0.39%	+10.45%	+0.31%	+0.60%	+0.10%	+3.36%	-0.89%

AHR

AHR fundamentals

AHR Q4 2025 Earnings

Earnings Call

You can ask Aime

AHR

AHR fundamentals

AHR Q4 2025 Earnings

Earnings Call

AHR Earnings Call Summary for Q4/20251:00 PM on Feb 27, 2026

AHR Earnings Call Summary for Q3/20251:00 PM on Nov 7, 2025

AHR Earnings Call Summary for Q2/20251:00 PM on Aug 8, 2025

AHR Earnings Call Summary for Q1/20251:00 PM on May 9, 2025

AHR Earnings Call Summary for Q4/20241:00 PM on Feb 28, 2025

You can ask Aime